Stockscreener 앱 받기
0.56
1.75%
-0.010
전일 마감가:
$0.57
열려 있는:
$0.559
하루 거래량:
25,421
Relative Volume:
0.01
시가총액:
$4.30M
수익:
-
순이익/손실:
$-10.31M
주가수익비율:
-0.2403
EPS:
-2.3308
순현금흐름:
$-6.32M
1주 성능:
-1.82%
1개월 성능:
+6.67%
6개월 성능:
-32.77%
1년 성능:
-72.41%
1일 변동 폭
$0.542
$0.57
1주일 범위
$0.5403
$0.5749
52주 변동 폭
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Compare GLMD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.56 | 4.30M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-05-22 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 개시 | Craig Hallum | Buy |
| 2020-01-30 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 개시 | Canaccord Genuity | Buy |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-08-02 | 재확인 | Maxim Group | Buy |
| 2018-07-13 | 개시 | Stifel | Buy |
| 2018-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2018-02-14 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 개시 | ROTH Capital | Buy |
| 2017-08-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 재확인 | Maxim Group | Buy |
| 2016-08-01 | 재확인 | Maxim Group | Buy |
| 2016-07-06 | 재개 | ROTH Capital | Buy |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
| 2015-05-06 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
GLMD Forecast — Price Target — Prediction for 2027 - TradingView
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
GPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure - The Globe and Mail
Galmed completes acquisition of medical device firm Colospan - Investing.com UK
Galmed Pharmaceuticals finishes restructured Colospan deal - grafa.com
Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd. - TradingView
Galmed completes acquisition of medical device firm Colospan By Investing.com - Investing.com Nigeria
Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout - Stock Titan
Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout - Stock Titan
Galmed buys CG-100 maker Colospan, eyes faster EU sales - Stock Titan
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Declines 3.37% as Shares Approach Key Support at $0.55Put Flow Alert - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) Institutional Confidence - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galmed Pharmaceuticals (GLMD) Slips 7.31% as Stock Tests Key Support at $0.54New Highs New Lows - newsline.com
GLMD Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Recovery Stocks - newsline.com
Maxim Group Maintains Galmed Pharmaceuticals(GLMD.US) With Hold Rating, Announces Target Price $0.55 - Moomoo
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market - Fierce Biotech
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed Pharmaceuticals Ltd (GLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):